Over a period of 20 years, the patients who met the following characteristics were identified by treating physicians: long-term disease-free survival, HER2-positive cancer, any HER2-directed therapy, any bone-directed therapy, and any endocrine therapy. This evidence concerns the gene ERBB2 and cancer.